Status and phase
Conditions
Treatments
About
This trial is a 52-week, open-label extension trial to investigate safety and to explore efficacy of Org 50081 (Esmirtazapine) in participants who completed Protocol 176001 (P05706) (NCT00482612) or 176002 (P05707) (NCT00506389). Participants who have completed Protocol P05706 or P05707, and are willing to continue treatment with Esmirtazapine, can participate in Protocol 176004 (P05708) after signing informed consent.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
346 participants in 1 patient group
There are currently no registered sites for this trial.
Start date
Dec 07, 2006 • 18 years ago
End date
Aug 17, 2009 • 15 years ago
Results posted
ViewJul 30, 2014 • 10 years ago
Today
Jan 22, 2025
Lead Sponsor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal